Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in T2DM and CKD: A Secondary Analysis of the SCORED Trial

CONCLUSIONS: In this exploratory analysis using the complete laboratory dataset, sotagliflozin reduced the risk of kidney and cardiorenal composite endpoints in patients with type 2 diabetes and CKD.PMID:38277468 | DOI:10.2215/CJN.0000000000000414

Source: Clinical Journal of the American Society of Nephrology : CJASN - January 26, 2024 Category: Urology & Nephrology Authors: Vikas S Sridhar Deepak L Bhatt Ayodele Odutayo Michael Szarek Michael J Davies Phillip Banks Bertram Pitt Ph Gabriel Steg David Z I Cherney Source Type: research